Cargando…
Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396100/ https://www.ncbi.nlm.nih.gov/pubmed/36016731 http://dx.doi.org/10.21037/hbsn-22-143 |
| _version_ | 1784771854503772160 |
|---|---|
| author | Kudo, Masatoshi |
| author_facet | Kudo, Masatoshi |
| author_sort | Kudo, Masatoshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9396100 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93961002022-08-24 Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma Kudo, Masatoshi Hepatobiliary Surg Nutr Editorial AME Publishing Company 2022-08 /pmc/articles/PMC9396100/ /pubmed/36016731 http://dx.doi.org/10.21037/hbsn-22-143 Text en 2022 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Kudo, Masatoshi Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma |
| title | Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma |
| title_full | Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma |
| title_fullStr | Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma |
| title_full_unstemmed | Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma |
| title_short | Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma |
| title_sort | durvalumab plus tremelimumab in unresectable hepatocellular carcinoma |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396100/ https://www.ncbi.nlm.nih.gov/pubmed/36016731 http://dx.doi.org/10.21037/hbsn-22-143 |
| work_keys_str_mv | AT kudomasatoshi durvalumabplustremelimumabinunresectablehepatocellularcarcinoma |